Marwan Fakih

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-...

Lancet (London, England) · 15 november 2025

Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic c...

European journal of cancer (Oxford, England : 1990) · 9 september 2025

Health-related quality of life in patiënten met KRASG12C-mutated chemorefractory metastatic colorectal cancer treated...

The Lancet. Oncology · 2025-09

Totale overleving Analysis of the Fase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Ch...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025-07

Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal ...

Lancet (London, England) · 14 juni 2025

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patiënten met RAS/BRAF Wild-Type, HER2-Positive, Meta...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 april 2025

Trifluridine-tipiracil plus bevacizumab bij refractair gemetastaseerd CRC: SUNLIGHT fase III

The New England journal of medicine · 4 mei 2023

Binimetinib-encorafenib-cetuximab bij BRAF V600E-gemuteerd gemetastaseerd CRC: BEACON fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 juni 2019

Atezolizumab met of zonder cobimetinib versus regorafenib bij eerder behandeld gemetastaseerd CRC: IMblaze370

The Lancet. Oncology · 2019-06

Publicaties op Oncologisch.com